Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

Exclusion Criteria

• •Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. (Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ cancers.)
• •Has a known active central nervous system metastasis and/or carcinomatous meningitis.
• •Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody/components of the study treatment(s).
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy.
• •Has a history of vasculitis.
• •Has an active infection requiring systemic therapy.
• •Has symptomatic ascites or pleural effusion.
• •Has interstitial lung disease that has required oral or intravenous glucocorticoids to assist with management.
• •Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
• •Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Note: Participants who have had a stem cell transplant \>5 years ago are eligible as long as there are no symptoms of graft-versus-host disease \[GVHD\].)
• •Has a known history of human immunodeficiency virus (HIV) infection.
• •Has known active Hepatitis B or known active Hepatitis C virus infection.
• •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.
• •Has not fully recovered from any effects of major surgery without significant detectable infection.
• •Has received prior systemic anti-cancer therapy including investigational agents or has used an investigational device within 28 days prior to the first dose of study treatment. (Notes: Participants must have recovered from all AEs due to previous therapies to ≤Grade 1 or baseline. Prior exposure to immunotherapeutics is allowed, including programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, provided the participant did not experience ≥Grade 3 drug-related toxicity on monotherapy with a PD-1 or PD-L1 inhibitor.
• •Has been previously treated with an Indoleamine-2,3-dioxygenase-1 (IDO1) inhibitor (e.g., epacadostat, BMS-986205)
• •Has received prior radiotherapy within 2 weeks of start of study treatment.
• •Is receiving a monoamine oxidase inhibitor (MAOI) or any drug which has significant MAOI activity (e.g., meperidine, linezolid, methylene blue) within the 21 days before screening, or has a history of Serotonin Syndrome after receiving serotonergic drugs.
• •Is expected to require any non-protocol antineoplastic therapy while on study.
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy in excess of replacement doses (the equivalent of prednisone ≤10 mg/day is acceptable), or on any other form of immunosuppressive medication.
• •Has received a live-virus vaccine within 30 days prior to first dose of study medication.